https://www.selleckchem.com/pr....oducts/gw-441756.htm
Sustained virological response rate was significantly lower for patients with hepatocellular carcinoma treatment (91%) than for patients without history of hepatocellular carcinoma treatment (98%, = 0.004). One patient (0.4%) discontinued treatment due to drug-induced pneumonia. Dose reduction or interruption of ribavirin was required for 12.1% (32/265) of patients because of anemia, including 7.7% (14/182) of patients 75-years-old and 21.7% (18/83) of patients ≥ 75-years-old ( = 0.002). Although ribavirin dose reduction or inter
Curtir
Comentario
Compartilhar
